Mazdutide tested for gout flares in obese adults
Investigator-led Phase 4 single-arm study will enroll 30 patients with obesity, gout and hyperuricemia.
PR
By Priya Raman · Science Reporter
Sep 17 08:00 ETSource: ClinicalTrials.gov
The wire
- 01A not-yet-recruiting Phase 4 open-label study will assess mazdutide's effect on annualized gout flare rate.
- 02Extends GLP-1 research into gout and hyperuricemia beyond weight loss.
- 03Enrollment has not begun; single-arm design limits conclusions.
From the source
Read at clinicaltrials.govMazdutide for Weight Management and Gout in Adults With Obesity
NCT07824895 · PHASE4 · NOT YET RECRUITING · Sponsor: Hongwei Jiang · Conditions: Gout, Obesity (BMI>30), Hyperuricemia. This is a single-arm, open-label, pre-post controlled study to evaluate the effect of Mazdutide on the annualized flare rate (AFR) in adults with obesity and gout. The study will enroll 30 subjects aged 18 to 65 years with a Body Mass Index (BMI) ≥ 30.0 kg/m². Eligible participants must have a confirmed diagnosis of gout and a history of at least 2 gout flares in the past 6 months. The primary obj
Source URL https://clinicaltrials.gov/study/NCT07824895